PMID- 25258536
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140926
LR  - 20220310
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 10
DP  - 2014
TI  - Factors affecting discontinuation of initial treatment with paroxetine in panic 
      disorder and major depressive disorder.
PG  - 1793-8
LID - 10.2147/NDT.S68670 [doi]
AB  - OBJECTIVE: The aims of the present study were to analyze the association between 
      discontinuation of paroxetine (PAX) and the genetic variants of the polymorphism 
      in the serotonin transporter gene-linked polymorphic region (5-HTTLPR) in 
      Japanese patients with panic disorder (PD) and major depressive disorder (MDD). 
      METHODS: The 5-HTTLPR genotype was determined by polymerase chain reaction 
      method. PAX plasma concentration was measured by high-performance liquid 
      chromatography to confirm adherence. RESULTS: When comparing between the PD and 
      MDD patients with the chi-square test and Fisher's exact test, the PD patients 
      had a significant and higher discontinuation rate due to non-adherence than did 
      the MDD patients (13.5% [7/52] versus 0% [0/88], respectively; P<0.001). MDD 
      patients had a significant and higher discontinuation rate due to untraceability 
      than PD patients (12.5% [11/88] versus 1.9% [1/52]; P=0.032). Multilogistic 
      regression revealed a tendency for the long/short and short/short genotypes to 
      affect discontinuation due to adverse effects in PD patients (25.0% versus 6.3%, 
      respectively; P=0.054). CONCLUSION: The results indicate that the 5-HTTLPR 
      genotype might contribute to the discontinuation of initial PAX treatment due to 
      adverse effects in PD patients.
FAU - Aoki, Akiko
AU  - Aoki A
AD  - Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, 
      Japan.
FAU - Ishiguro, Shin
AU  - Ishiguro S
AD  - Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, 
      Japan.
FAU - Watanabe, Takashi
AU  - Watanabe T
AD  - Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, 
      Japan.
FAU - Ueda, Mikito
AU  - Ueda M
AD  - Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, 
      Japan.
FAU - Hayashi, Yuki
AU  - Hayashi Y
AD  - Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, 
      Japan.
FAU - Akiyama, Kazufumi
AU  - Akiyama K
AD  - Department of Biological Psychiatry and Neuroscience, Dokkyo Medical University 
      School of Medicine, Tochigi, Japan.
FAU - Kato, Kazuko
AU  - Kato K
AD  - Sakura La Mental Clinic, Tochigi, Japan.
FAU - Inoue, Yoshimasa
AU  - Inoue Y
AD  - Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, 
      Japan.
FAU - Tsuchimine, Shoko
AU  - Tsuchimine S
AD  - Department of Neuropsychiatry, Hirosaki University Graduate School of Medicine, 
      Aomori, Japan.
FAU - Yasui-Furukori, Norio
AU  - Yasui-Furukori N
AD  - Department of Neuropsychiatry, Hirosaki University Graduate School of Medicine, 
      Aomori, Japan.
FAU - Shimoda, Kazutaka
AU  - Shimoda K
AD  - Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20140918
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
PMC - PMC4174019
OTO - NOTNLM
OT  - discontinuation
OT  - major depressive disorder
OT  - panic disorder
OT  - paroxetine
EDAT- 2014/09/27 06:00
MHDA- 2014/09/27 06:01
PMCR- 2014/09/18
CRDT- 2014/09/27 06:00
PHST- 2014/09/27 06:00 [entrez]
PHST- 2014/09/27 06:00 [pubmed]
PHST- 2014/09/27 06:01 [medline]
PHST- 2014/09/18 00:00 [pmc-release]
AID - ndt-10-1793 [pii]
AID - 10.2147/NDT.S68670 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2014 Sep 18;10:1793-8. doi: 10.2147/NDT.S68670. 
      eCollection 2014.